Case Report
Copyright ©The Author(s) 2020.
World J Clin Cases. Sep 26, 2020; 8(18): 4151-4161
Published online Sep 26, 2020. doi: 10.12998/wjcc.v8.i18.4151
Table 1 Summary of studies reporting prevalence of celiac disease in Sjogren syndrome
Ref.SS (n)CountryCD prevalence (SS + CD)Serological criteriaHistological criteria
Iltanen et al[16]34 SS+, 28 controlsFinland14.7% (n = 5)SS+ CD; 3/5 IgA EMA+; 4/5 IgA AGA+; 5/5 IgA EMA or AGA +; SS – CD; 0/28 IgA EMA +; 9/28 IgA AGA +All 5 seropositive - Marsh 3
Szodoray et al[17]111 SS+Hungary4.5% (n =5 )6/111 tTG and/or AGA and/or EMA +5/6 CD+, one with jejunitis
Bartoloni et al[18]354 SS+, 14298 controlsItaly7.1% (n = 25), 6.8% (n = 24) previously diagnosed CD, 1 latent CD24 previously diagnosed (2013 WGO guideline criteria), 1 IgA tTG+All 25
Bizzaro et al[19]100 SS+Italy, Israel1% (n = 1)1 IgG tTG + (IgA tTG-)Histology not done
Luft et al[20]50 SS+, 50 controls 40 disease-controls (CD+)Canada12% (n = 6)6 IgA tTG +5/6 biopsy-proven CD
Caio et al[21]52 SS+Italy5.8% (n = 3)3/42 IgA tTG+, IgG DGP + and IgA EMA+Histology not used
Table 2 Summary of studies reporting prevalence of Sjogren syndrome in celiac disease
Ref.CD (n)CountrySS prevalence (SS + CD)Diagnostic criteria
Erbasan et al[25]82Turkey1.2%29.3% dry eye, 24.4% dry mouth; 14.6% ANA+
Bibbò et al[26]255Italy2.4%
Caglar et al[27]31Turkey6.5%12.9% ANA+; 6.5% SS-A/Ro+ and/or SS-B/La+
Collin et al[28]335Finland3.3%
Ayar et al[29]81Turkey4.9%23.5% dry eye, 27.2% dry mouth
Table 3 Clinical scenarios needing the search of celiac disease in Sjögren syndrome patients or Sjögren syndrome in celiac disease patients
When to consider CD in SS patients?
When to consider SS in CD patients?
Suggestive gastrointestinal symptoms; Suspected malabsorption; Hypogammaglobulinemia and low levels of total protein; High levels of transaminases without evident cause; Anemia of unknown cause; Herpetiform dermatitis; Autoimmune thyroiditis (frequent in SS patients)[47]1Dry eyes and dry mouth symptoms; Enlarged parotid glands; Hypergammaglobulinemia and high levels of total protein; Polyneuropathy; Arthritis (arthralgias?); Purpura
Table 4 Future agenda
Describing the prevalence of SS in patients with CD using the new classification criteria for SS
Describing the prevalence of CD in SS patients using newer generation serology tests
Prospective studies in patients with both conditions regarding evolution and prognosis, especially regarding the possible additive risk of lymphoma
Describing the role of gluten free diet regarding SS symptoms in patients associating both diseases
Developing clear recommendations for screening for SS in CD and for CD in SS